Resource Hub

Organizations and Advocacy Groups

The following organizations provide disease education, additional support, and expert opinions. This list of independent organizations is provided as an additional resource for obtaining information related to MDS and MF and does not indicate endorsement by Bristol Myers Squibb of an organization or its communications.

MDS

MF

Oncology

Guideline Committees

Tools

Risk Stratification: MDS

Risk Stratification: MF

Quality of Life Measures: MDS

Quality of Life Measures: MF

Educational Resources

Continuing Medical Education

For Patients

Independent Learning: MDS

Independent Learning: MF

Acknowledgments

We would like to thank the Spotlight on Anemia Steering Committee for their continued partnership, perspectives, and commitment to patient care.

David Sallman, MD (Chair)

Moffitt Cancer Center

Namrata Chandhok, MD

Sylvester Comprehensive Cancer Center

Yunying (Erin) Chen, NP

UCLA Health

Carter Davis, MD

Ochsner Health

Rebecca Garcia Hunt, PharmD

Atrium Health Wake Forest Baptist

Zachary Hanson, MD

Loma Linda University Cancer Center

Sanjay Juneja, MD

Mary Bird Perkins Cancer Center

Sanam Loghavi, MD

University of Texas MD Anderson Cancer Center

Yazan Madanat, MD

UT Southwestern Medical Center

Neil Palmisiano, MD

Rutgers Cancer Institute of New Jersey

Samantha Salvatora, PA

University of Texas MD Anderson Cancer Center

Download an MDS diagnosis pocket guide →

Diagnosing MDS requires an extensive series of tests, but it is also important to have a high clinical suspicion to identify risk factors for developing MDS, such as advancing age.Hasserjian RP et al. Blood. 2023;142:2247-2257. Sekeres MA. Hematol Oncol Clin North Am. 2010;24:287-294.

Download an MDS treatment pocket guide →

Delays in treatment may result in more severe anemia, reduced quality of life, and increased mortality risk. Early treatment is essential to improve long-term outcomes.Kaka S et al. Transfus Med. 2022;32(1):3-23.

Download an MF diagnosis pocket guide →

Diagnosing MF requires a thorough diagnostic workup alongside high clinical suspicion, particularly in patients with established risk factors, such as advancing age.Prakash S, Orazi A. Am J Clin Pathol. 2022;157(4):518-530. Shallis RM et al. Blood Rev. 2020;42:100706.